20
Participants
Start Date
December 31, 2011
Primary Completion Date
July 31, 2013
Study Completion Date
January 31, 2014
Ranibizumab
A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Ranibizumab
A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Vitreo-Retinal Associates, PC, Worcester
Collaborators (1)
Genentech, Inc.
INDUSTRY
Vitreo-Retinal Associates, PC
OTHER